Clinical Trials Directory

Trials / Completed

CompletedNCT03209219

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the participants will receive IFNα2a while the other half will receive CsA.

Detailed description

Detailed description: Both CsA and IFNα2a have been shown to be effective for long-term control of BDU, however, randomized prospective comparative studies are scarce, particularly in East Asian populations. Our preliminary data gave us the impression that IFNα2a might be more effectiveness than CsA in long-term control of refractory BDU, and this study aimed to compare their effectiveness and safety profiles in a well-designed prospective study. Refractory BDU is defined as relapse of posterior or pan- uveitis with at least 10mg daily prednisone (or equivalent) and one traditional immunomodulatory treatment (IMT) agents. The acute attack is controlled with large dose oral corticosteroid (60mg daily prednisone) for 4 weeks, and then the patients are randomly assigned to the IFN arm and the CsA arm, in which patients are treated with IFNα2a (3×10\^6 IU qd for 4 weeks and qod thereafter) and CsA (100mg bid), respectively, along with a fixed tapering regimen of corticosteroid. Patients were followed up until relapse, or for 12 months.

Conditions

Interventions

TypeNameDescription
DRUGInterferon Alfa-2A3×10\^6 IU, subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
DRUGCyclosporine Pill100mg, oral, bid

Timeline

Start date
2017-06-30
Primary completion
2020-08-31
Completion
2021-01-31
First posted
2017-07-06
Last updated
2021-02-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03209219. Inclusion in this directory is not an endorsement.